BSE filing, NSE: KPL. Summary written from the filing by ALFA Finder's alert engine.
Kwality Pharmaceuticals Ltd: key numbers
- Share price
- ₹3,473.55
- Market cap
- ₹3,604 Cr
- Revenue (annual)
- ₹503.1 Cr
- Net profit (annual)
- ₹67.35 Cr
- P/E (TTM)
- 44.5×Sector 45.9×
- Promoter holding
- 54.86%+0.00% QoQ
- FII holding
- 2.50%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Kwality Pharmaceuticals Ltd
All →Kwality Pharmaceuticals Other Announcement
Kwality Pharmaceuticals Ltd filed its shareholding pattern for the quarter ended September 30, 2026, as required by SEBI regulations.
Kwality Pharmaceuticals Capacity Expansion
Kwality Pharmaceuticals acquired 4 acres adjacent to its Amritsar plant to build a fully automated facility with 10+ production lines. Completion is targeted by Q4 FY2028 with full operations by Q2 FY2029.
- Execution
- Completion by Q4 FY2028; full operations by Q2 FY2029
- manufacturing production lines (injectable + oral solid + ophthalmic)
- 10 production lines
Kwality Pharmaceuticals Management Change
Kwality Pharmaceuticals has regularized the appointment of Mr. Swanith Kapoor as Independent Director and reappointed Mr. Aditya Arora as Whole Time Director for five years.
Kwality Pharmaceuticals Annual General Meeting
Kwality Pharmaceuticals Limited conducted its 43rd Annual General Meeting on August 31, 2026, via video conferencing. The meeting covered routine shareholder resolutions and director re-appointments.
Kwality Pharmaceuticals Earnings Call Transcript: Key Takeaways
Kwality Pharma Q1FY27 con-call highlights revision of FY27 revenue target to ₹700Cr+ with 26-27% EBITDA margins, driven by niche injectable registrations in LATAM and MENA regions.
- Call
- Guides 30% growth
Kwality Pharmaceuticals Investor Presentation: Key Takeaways
Kwality Pharma reported strong Q1FY27 performance with revenue up 45.7% YoY. Management raised FY27 revenue guidance to INR 700+ Cr and improved margin outlook.
- Call
- Guides 39% growth
Other board meeting date announcements
All →Novartis India Board Meeting Date
Evonile Pharma will hold a board meeting on November 4, 2026 to approve the rights issue letter of offer. BSE granted in-principle approval for the rights issue.
CHD Chemicals Board Meeting Date
CHD Chemicals intimated a board meeting on 04 Nov 2026 to consider unaudited half-yearly results for September 2026. Trading window remains closed until 06 Nov 2026.
Max Estates Board Meeting Date
Max Estates Limited has informed exchanges that its board will meet on 4 November 2026 to consider unaudited results for the quarter and half year ended 30 September 2026. The trading window stays closed until 6 November 2026.
GKP Printing & Packaging Board Meeting Date
G.K.P. Printing & Packaging announced a board meeting on 4 November 2026 to approve unaudited results for the quarter ended 30 September 2026. Trading window has been closed for insiders since 1 October 2026.
ADF Foods Board Meeting Date
ADF Foods will hold a board meeting on November 5, 2026 to consider unaudited results for the quarter and half year ended September 30, 2026. The meeting will also consider an interim dividend for FY2026-27.
MKP Mobility Board Meeting Date
MKP Mobility will hold a board meeting on November 6, 2026 to consider unaudited standalone and consolidated results for the quarter and half year ended September 30, 2026. Trading window remains closed until 48 hours after results.